CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
C

sarcoidosis

Comorbid ConditionsDisease / conditionrisknon modifiable
8
evidence score
PREVENT status

Not a PREVENT input variable.

Causal support

observational only

Score components
lit volume: 3meta-analyses: 0trials: 4.8genetic: 0MR bonus:

References (1)

0 meta-analyses / systematic reviews

Clinical trials (2)

NCTTitleStatusTypeInterventions
NCT04758650Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosisTERMINATEDINTERVENTIONAL68GaNOTA-Anti-MMR-VHH2
NCT02888080A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary SarcoidosisCOMPLETEDINTERVENTIONALACZ885, Placebo

Genetic associations (0)

None linked.